We compared a strip test employing recombinant K39 (rK39) antigen and protein A/colloidal gold as read-out agents with the rK39 ELISA for IgM and IgG antibodies and the direct agglutination test (DAT) using 55 sera from patients with parasitologically con®rmed visceral leishmaniasis (VL). The rK39 strip test was positive in 37/55 (67%), the DAT in 50/55 (91%) at ³ 1 : 1600 cut-off value and in 47/55 (85%) at ³ 1 : 6400 cut-off value. The rK39-ELISA gave positive IgG results for all sera; those who had a positive strip test had signi®cantly higher IgG levels than those with a negative strip test (31.1 (SD 3.6) and 17.7 U/ml (SD 9.8), respectively, P < 0.0001). A total of 31/55 (56%) sera showed a positive IgM result; of these 27 (49%) had a positive strip test. We tested 115 apparently cured VL patients with the strip test during follow-up; 68 were also tested with DAT. In the strip test, 25±43% of patients had a positive result at time points 3, 6, 9 and 12 months after treatment; for DAT (cut-off ³ 1 : 1600) these results were 67±83%. In neither test did a signi®cant decrease in positivity rates occur over time (P 0.37 for the strip test, P 0.17 for the DAT). No correlation (P 0.33) was found between a positive strip test and a positive DAT result (cut-off ³ 1 : 1600), indicating that the strip test and DAT are complementary rather than interchangeable. Of 61 endemic controls two (3%) had a positive strip test result; both had a positive leishmanin skin test. The rK39 strip test has the ideal format for use in the ®eld, but its sensitivity is limited; like DAT, but to a lesser extent, it remains positive after treatment.
Introduction
Visceral leishmaniasis (VL) or kala-azar is endemic in the Sudan; in recent years a major epidemic in an area not previously known to be endemic has occurred, as well as a major outbreak in the endemic area in eastern Sudan (Perea et al. 1989; El-Hassan et al. 1995) . Classically, diagnosis is made by the demonstration of Leishmania amastigotes in aspirates from lymph nodes, bone marrow or spleen; these procedures have a sensitivity of 58, 70 and 96%, respectively (Zijlstra et al. 1992) . Serological tests have the advantage of being safe and less invasive and can be done in large numbers. Several serological tests have been developed, of which the direct agglutination test (DAT) has been evaluated extensively. In a hospital-based study this test was found to have good sensitivity of 94% but speci®city was only 72% (Zijlstra et al. 1992) .
Speci®city is in¯uenced mainly because titres remain high for months or even years after successful treatment (Zijlstra et al. 1991a) . Cross-reactions with other pathogens may also occur . Several improvements in antigen quality and delivery have been made (Harith et al. 1995; Meredith et al. 1995) . Although the DAT was adapted for ®eld use (Meredith et al. 1995; Zijlstra et al. 1997) , there is a need for a simple, rapid and accurate test with good sensitivity and speci®city that can be used in the ®eld and for which no speci®c expertise is required. Recently, an ELISA using a recombinant antigen derived from a 39-amino acid repeat in L. chagasi (rK39) was developed; the antibody response to rK39 was found to be largely VL-restricted, as no reactivity was found with pathogens other than Leishmania and as with the DAT, there was virtually no response in patients with cutaneous leishmaniasis (El-Sa® & Evans 1989 1 ; Burns et al. 1993; Qu et al. 1994) . Evaluation of this rK39-ELISA in the Sudan con®rmed good sensitivity (93%), but also in this test, titres may remain high for up to 24 months after successful treatment (Zijlstra et al. 1998) . The rK39 antigen was used for the development of a strip test which was found to have 100% sensitivity and 98% speci®city in India (Sundar et al. 1998) . Here we present the ®rst experience with this strip test in the Sudan and compare its performance with the rK39 ELISA and the DAT in patients with active VL and in patients who were followed up after completion of treatment.
Patients and methods
Fifty-®ve sera of patients with VL were tested; all patients were parasitologically con®rmed by demonstration of Leishmania amastigotes in either lymph node, bone marrow or spleen aspirates. Of these, 20 were from epidemic VL cases collected in 1990±91 at the Kala-azar Hospital in Khartoum, which was established to accommodate patients (mainly from the Nuer tribe) arriving from southern Sudan, where a major epidemic had occurred (Zijlstra et al. 1991b) . The remaining 35 sera came from endemic VL patients in Eastern Sudan from 1991 to 1996. These patients belonged to the Masaleet tribe. Sera were tested with the rK39 strip test, DAT and rK39-ELISA (IgM and IgG).
In addition, in April 1998, cured VL patients from the endemic area were followed up and tested with the rK39 strip test and DAT. All had been parasitologically con®rmed and treated at the Mede Âcins sans Frontie Áres (MSF) ± Holland treatment centre in Um-Kuraa with a course of sodium stibogluconate (Pentostam R , Glaxo Wellcome, UK) 20 mg/kg i.m. for 30 days.
After successful treatment, post-kala-azar dermal leishmaniasis (PKDL) frequently follows VL, since Leishmania parasites may persist in the skin for a variable period of time (Zijlstra et al. 1994; Gasim et al. 1998) . As it is possible that these parasites may continue to elicit an antibody response, the follow-up patients were divided into two groups: those who were cured, but had PKDL at the time of testing, and those who were cured without PKDL. In all patients, time since end of treatment was recorded. Lastly, the rK39 strip test and the DAT were compared in healthy endemic controls.
The properties of the strip test (Arista Biologicals, Inc, Bethlehem PA, USA) have been described by Sundar et al. (1998) . The procedure was as follows: for patients with active VL, 50 ll of serum was added to 100 ll of normal saline in a test tube; the strip test was placed upright in the tube and the¯uid was allowed to migrate along the strip.
In the follow-up patients, a drop of blood was placed on the strip and 100 ll of saline was added. The test was only considered valid when a control line (irrespective of its intensity) appeared. The test result was read independently by two individuals within 5±10 min. Any test line that appeared was considered as a positive result irrespective of its intensity.
The DAT was performed as described Zijlstra et al. 1991a) . The cut-off point for a positive test may vary in different areas and depends on the prevalence of VL; for the Sudan it lies between titres 1 : 1600 and 1 : 6400 (E. E. Zijlstra, personal observations) and the strip test was therefore compared with both cut-off points.
rK39-ELISA was performed as previously described with slight modi®cation (Qu et al. 1994) . Brie¯y, the optimal concentration of rK39 antigen (50 ng/well) was coated onto microtitre plates in phosphate buffered saline (PBS pH 7.2). Prior to detection of speci®c IgM antibodies against Leishmania, serum samples were preabsorbed to remove IgG antibodies using Gullsorb (Gull Laboratories, Salt Lake City, USA). For IgM and IgG detection serum samples were diluted 1 : 100 in sample buffer and incubated for 1 h at 37°C. Binding of speci®c IgM and IgG serum antibodies was detected using goat antihuman IgM peroxidase conjugate (DAKO, Glostrupp, Denmark) and goat antihuman IgG peroxidase conjugate (Biosource, USA). Plates were developed by adding tetramethylbenzidine as substrate and optical density was measured at 450 nm (OD 450). Results were considered positive if the OD 450 value exceeded the mean of the negative control samples plus three times the standard deviation.
Statistics
After entry in EPI-Info, analysis was done using the SPSS statistical package. Proportions were compared using the chi-squared test with Yates' correction, or Fisher's exact test, where appropriate. Means were compared using Student's t -test for normally distributed data or the Kruskal±Wallis test for data that did not have a normal distribution. To explore differences in the trend of converting to a negative result after treatment, we used logistic regression with the DAT result and rK39 strip test result as the dependent variables and time as the covariable.
Results

Practical considerations
In contrast to the control line, the test line in the strip test was faint in some cases and therefore it was sometimes dif®cult to decide whether a reading was positive or negative. Any line that appeared was regarded as a positive strip test result. In addition, as the ambient temperature in the ®eld often exceeds 40°C and the relative humidity is < 30%, care must be taken that the sample does not dry before the control line is reached. The test does not work with undiluted whole blood; the sample should be diluted at least two-fold. In this study, normal saline was used as a diluent; however, un®ltered water gave similar results (data not shown). Similarly, in the laboratory, serum had to be diluted two-fold to allow the solution to run beyond the control line.
Con®rmed VL patients
A total of 55 parasitologically con®rmed patients with VL were tested with the strip test; 20 from the epidemic VL area and 35 from the endemic VL area; the mean age of patients from the epidemic VL area was 17.3 years (SD 12.5) while patients from the endemic area were on average 10.8 years (SD 6.2) old (P 0.01). There was no signi®cant difference in positivity rate in the strip test between these two groups (15/20 (75%) and 22/35 (63%) respectively, (P 0.53)). The sensitivity of the strip test (67%) in all 55 parasitologically con®rmed patients was lower than that of the DAT at either cut-off point (91 and 85%, respectively), which was statistically signi®cant (Table 1) . Comparing the patients from the epidemic and endemic areas, only in the patients from the endemic area did the strip test show less sensitivity than the DAT for a cut-off titre ³ 1 : 1600 (P 0.003), whereas for the DAT with a cut-off titre ³ 1 : 6400 the difference did not reach signi®cance (P 0.06). In 38/55 (69%) the rK39 strip test showed a similar result (both tests positive or both negative) and in 17/55 (31%) a discrepant result compared with DAT when the cut-off titre was chosen as ³ 1 : 1600; for a cut-off titre with the DAT of ³ 1 : 6400, these results were 35/55 (64%) and 20/55 (36%), respectively, for similar and discrepant results (Table 2 ). There was no signi®cant difference between the outcome of the rK39 strip test and the DAT for either cut-off titre (P 0.19 for DAT ³ 1 : 1600 and P 0.52 for DAT ³ 1 : 6400, Table 2 ).
All patients tested were positive in the rK39-ELISA for IgG; there was no difference between IgG levels in patients from the epidemic or endemic area (mean IgG 26.8 (SD 10.1) and 27.2 U/ml (SD 8.1), respectively, P 0.86). For all patients combined, those who had a positive strip test had IgG levels between 21.0 and 37.0 U/ml (mean 31.3, SD 3.6), whereas those with a negative strip test had IgG levels of 0.2±33.0 U/ml (mean 17.7, SD 9.8). This difference was statistically highly signi®cant (P < 0.0001) ( Table 2 ).
In the rK39-ELISA for IgM, 31/55 (56%) of all patients tested positive; those with a positive strip test had higher levels of IgM than those with a negative strip test (mean 2.8 U/ml (SD 2.3) and 0.7 U/ml (SD 0.5), respectively: P 0.0002); in 14/55 (25%) cases the strip test and the IgM result disagreed (Table 2) .
Ex-VL patients
In the 115 cured VL patients who were followed up after treatment, the positivity rate in the rK39 strip test was lower at all time points than that using the DAT (Table 3 ). For all patients tested, in neither the rK39 strip test nor the DAT was there a signi®cant decrease in positivity rate over time (P 0.37 and 0.17, respectively). There was no difference in positivity rates between those who were cured with current PKDL and those who were cured without ever having had PKDL (for rK39-strip test P 0.88 and for DAT P 0.07). There was no correlation between the strip test result and a positive DAT result (cut-off ³ 1 : 1600) (P 0.33). Positive strip test results could be found in patients with the whole range of DAT titres (Figure 1 ). 
Endemic controls
Sixty-one individuals (mean age 9.5 years, SD 13.7) were tested by DAT and rK39 strip test; in 57 cases (93%) both tests were negative (cut-off for DAT ³ 1 : 6400) and in none were both tests positive. Two patients had positive strip test results; both had DAT titres 1 : 200 and were positive in the leishmanin skin test. One of these patients had no splenomegaly and a negative lymph node aspirate; the other individual had splenomegaly of 5 cm; she was not available for follow-up. Two individuals had a positive Change of positive DAT result over time: P = 0.17; Change of positive rK39 strip test result over time: P = 0.37. DAT (titre 1 : 6400 and ³ 1 : 102 400) and a negative strip test result. Both were healthy; there was no splenomegaly. Further evaluation showed a positive leishmanin skin test. No parasitological diagnosis could be carried out and neither patient was followed up further.
Discussion
The rK39 strip test has the ideal format for use under ®eld conditions. It is quick and no special equipment is needed. However, care should be taken to add enough diluent, as it is not possible to do the test on undiluted whole blood or serum. This is particularly important under ®eld conditions: in Sudan ambient temperatures are > 40°C and the relative humidity is low. Normal saline or (un®ltered) water can be used in the test. The test is read by eye which renders it subjective in its interpretation as in some cases the test line is barely discernable from the background and the result may therefore be subject to discussion. The rK39 strip test has lower sensitivity than the DAT (67% and 90%, respectively) and in only 69% of patients was there complete agreement between the strip test and DAT result (titre ³ 1 : 1600). No corrrelation was found between the two tests, suggesting that they may complement rather than replace each other. In the patients from the endemic area, the rK39 strip test was less sensitive than DAT (cut-off ³ 1 : 1600) whereas this was not found for patients from the epidemic area. Although no differences were found in mean anti-rK39 IgG levels, other factors may need to be taken into account, such as younger age, ethnic background, severity of infection, time since infection, etc.
The rK39 strip test had markedly less sensitivity in our study than that reported from India (Sundar et al. 1998) . The reason for this is unclear, but differences in antibody responses elicited may play a role, as was noted for Indian and Chinese sera in the rK39-ELISA (Singh et al. 1995) .
It is generally accepted that strip tests as used in this study should be read within 5±10 min to avoid false positive results caused by non-speci®c reactions. However, reading of the strip test after 30 min and 24 h would have increased the sensitivity to 72 and 78%, respectively; all patients were parasitologically con®rmed and ®ve of seven patients who tested negative after 5±10 min but positive after 24 h also had a DAT ³ 1 : 6400 (data not shown), indicating that these are possibly true rather than false positive reactions. The strip test was signi®cantly better at detecting high IgG levels (> 21.0 U/ml) in the rK39-ELISA and those who were negative in the strip test generally had lower IgG levels; accepting the readings after 24 h would have resulted in the strip test consistently detecting IgG levels > 21.0 U/ml. The optimal reading time of the strip test therefore remains to be carefully determined.
Irrespective of time of reading, the rK39 strip test was less sensitive than the rK39-ELISA. One possible explanation may be that in the latter plates are coated with rK39 antigen to which only anti-K39 IgG will bind, whereas in the strip test all IgG is bound to protein A/colloidal gold and a variable fraction thereof will be anti-K39 IgG.
We have only partially tested the speci®city of the strip test by testing healthy endemic controls of whom two had a positive test result. We did not test sera from patients other than those with Leishmania infection, but other studies have found no reactivity in sera from patients with other parasitic diseases or from non-endemic controls using either the rK39-ELISA or rK39-strip test (Singh et al. 1995; Badaro Â et al. 1996; Sundar et al. 1998) . Although traditionally speci®city is assessed by testing specimens from patients with other diseases or from healthy controls for Leishmania infection, it may be more relevant to describe speci®city in terms of the absence of active leishmanial disease. As tests such as rK39 strip test use speci®c antigens, cross-reactions with other diseases are becoming more and more unlikely, leaving the persistence of antibodies as a result of previous (subclinical) infection as the more important problem. This was demonstrated for the rK39-ELISA as well as for the DAT (Zijlstra et al. 1998) and it is reasonable to assume that this will also apply to the rK39 strip test. As with the DAT, positive strip test results were found in patients during follow-up of up to 12 months after completion of treatment, but the positivity rate was signi®cantly lower. No differences were found in positivity rates at various time-points during follow-up; the presence of PKDL did not in¯uence the positivity rates. The persistence of antibodies after treatment thus affects the speci®city of the strip test, which will be even lower should the test be adapted to increase sensitivity and detect lower levels of anti-rK39 IgG. As this was a cross-sectional study, no conclusions can be drawn on the decline of IgG levels in individual patients over time; however, we have shown in a previous study that IgG as detected by rK39 ELISA may remain detectable in individual patients for as long as 24 months post-treatment (Zijlstra et al. 1998) .
In its present form, the rK39 strip test has the ideal format for use in the ®eld but also has important limitations and should be used with caution. In general, a positive test result in a patient who presents with the classical clinical features of VL (chronic fever, (hepato-) splenomegaly and wasting) will support the diagnosis of VL. It should be noted that a positive test result may be the result of previous (subclinical) infection and therefore not relevant to the current illness. Under ®eld conditions it is not always clear from the history whether a patient who reports previous treatment for VL was correctly diagnosed at the time. A negative test result should not deter the attending clinician from attempting to diagnose VL by different methods. As with other serological tests, the rK39 strip test should be evaluated carefully in the area where it is to be used and in the context of the clinical picture.
